Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28917456 | 0.92 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL3414844 | 0.83 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL10260946 | 0.81 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL15085762 | 0.81 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL5546669 | 0.79 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL14157466 | 0.79 | CA14 (0.42) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL3315785 | 0.79 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL20237062 | 0.79 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14DGAT1 | |
| SCHEMBL24106653 | 0.78 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14CACNA1G | |
| SCHEMBL14443433 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3067355-B1 | CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE | MEIJI SEIKA PHARMA CO LTD (JP) | 2020-12-16 | — | — | EP | claimed |
| CN-111153903-A | Crystal of diazabicyclooctane derivative, preparation method and application thereof, and pharmaceutical composition | 明治制果药业株式会社 | 2020-05-15 | — | — | CN | claimed |
| EP-3050883-B1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVES AND INTERMEDIATES | MEIJI SEIKA PHARMA CO LTD (JP) | 2020-04-22 | — | — | EP | claimed |
| US-10604522-B2 | Processes for producing diazabicyclooctane compounds | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-03-31 | — | — | US | claimed |
| EP-3613741-A1 | PREPARATION OF A DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2020-02-26 | — | — | EP | claimed |
| EP-3613740-A1 | PREPARATION OF A DIAZABICYCLOOCTANE DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2020-02-26 | — | — | EP | claimed |
| US-20190031659-A1 | PROCESSES FOR PRODUCING DIAZABICYCLOOCTANE COMPOUNDS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-01-31 | — | — | US | claimed |
| US-10131665-B2 | Processes for producing diazabicyclooctane compounds | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-11-20 | — | — | US | claimed |
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | claimed |
| CN-105555787-B | Process for preparation of diazabicyclooctane derivatives and intermediates therefor | 明治制果药业株式会社 | 2017-08-08 | — | — | CN | claimed |
| US-20060030577-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | BATTISTA KATHLEEN | 2006-02-09 | — | — | US | claimed |
| EP-1601674-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO 4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-12-07 | — | — | EP | claimed |
| CN-1694883-A | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | JANSSEN PHARMACEUTICA NV (BE) | 2005-11-09 | — | — | CN | claimed |
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-07-22 | — | — | US | claimed |
| EP-1140895-B1 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-03-24 | — | — | EP | claimed |
| WO-2004022558-A2 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | claimed |
| CN-1343206-A | Cyclocompound | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-04-03 | — | — | CN | claimed |
| EP-1140895-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142955-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1receptor mediated disorders | OPRL1, GPR4, ADRA1D | HDAC6 1153/4885HDAC1 751/4885HDAC2 1440/4885 |
| US-20060030577-A1 | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders | OPRL1, ADRA1D, OPRD1 | HDAC6 1358/4885HDAC1 695/4885HDAC2 1605/4885 |
| US-10604522-B2 | Processes for producing diazabicyclooctane compounds | DHCR7, C9, CYCS | HDAC6 2499/4885HDAC1 2044/4885HDAC2 2372/4885 |
| US-20190031659-A1 | PROCESSES FOR PRODUCING DIAZABICYCLOOCTANE COMPOUNDS | DHCR7, C9, CYCS | HDAC6 2499/4885HDAC1 2044/4885HDAC2 2372/4885 |
| US-10131665-B2 | Processes for producing diazabicyclooctane compounds | DDT, ODC1, CYP51A1 | HDAC6 2174/4885HDAC1 3136/4885HDAC2 3326/4885 |
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | CLCN2, ODC1, KCNN4 | HDAC6 1990/4885HDAC1 1734/4885HDAC2 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.